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ysis, logistic analysis, survival analysis, and recursive partitioning decision analy-
sis were used to estimate the relationship between the financial impact of a new
drug indication and the probability of its reimbursement. The multivariable anal-
yses controlled for other clinical and economic variables that have been shown to
be correlatedwith the probability of reimbursement, including the cost per quality-
adjusted life-year gained. RESULTS: In all analyses, financial impact was a signif-
icant predictor of the probability of reimbursement. For example, in the logistic
analysis, the odds ratio of reimbursement for a drug submission with a financial
impact greater than A$10 million compared with A$0 or less was 0.12 (95% confi-
dence interval [CI]: 0.03-0.55); the odds ratio of reimbursement for a drug submis-
sion with a financial impact greater than A$0 up through A$10 million compared
with A$0 or less was 0.16 (95% CI: 0.04-0.60). Similar results were obtained in the
survival analysis. In the recursive partition decision analysis, the first split of the
data was for submissions with a positive financial impact compared with those
with a negative financial impact. CONCLUSIONS: In Australia, financial impact on
the health care system is an important determinant of whether a new drug is
recommended for reimbursement, even when cost-effectiveness estimates and
other clinical and economic variables are controlled.
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OBJECTIVES: Cellular therapies and regenerativemedicines, are poised to have the
same paradigm-shifting influence on healthcare as monoclonal antibodies (mABs)
and personalizedmedicine.While these therapies hold similarities to conventional
biopharmaceuticals, they also differ in material ways including attributes of both
medical devices and pharmaceuticals; use of multiple procedures to prepare and
deliver cells; and the potential to cure some diseases. Because of their complexity,
these technologies are also anticipated to be costly and face heavy scrutiny of
value. The objective of this research is to evaluate recent reimbursement policies
on regenerative medicines, compare them to current biopharmaceuticals, and
evaluate lessons for health economics and outcomes research (HEOR) and reim-
bursement planning. METHODS: A search of US HTAs from the Centers for Medi-
care and Medicaid Services, the Agency for Healthcare Research and Quality
(AHRQ), the BlueCross BlueShield Technology Evaluation Center and publicly avail-
able commercial payer coverage policieswas conducted to identify reimbursement
recommendations and supporting rationale. A review of the literature, including
the Cochrane Library and PubMed was also conducted using relevant MeSH terms
and text words to identify additional reimbursement issues associated with regen-
erative medicines. RESULTS: Although a nascent treatment area, over 15 technol-
ogy assessments and coverage policies on regenerative medicines were available
from US HTA agencies and payers. Different from most other technologies, some
noncoverage positions have been established prior to the emergence of specific
technologies or supporting evidence. The literature relevant to HEOR issues on
regenerativemedicines is particularly limited to date. CONCLUSIONS:While payer
policies on regenerativemedicines reflected decision factors commonly associated
with biopharmaceuticals, other factors beyond conventional biologics were iden-
tified. These factors include special evidentiary considerations for cell processing
steps, influence of the evidence-base supporting multi-procedural steps on reim-
bursement, and evaluation of the entire procedure vs. the biopharmaceutical
alone. Key considerations for HEOR are discussed.
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OBJECTIVES: The objective of this study was to understand what stakeholders in
US, EU5, Canada & Australia interpret as disease modification. In chronic progres-
sive conditions, disease modification versus symptom control is the ultimate goal
of healthcare specialists. However, there is no consensus on what “disease modi-
fication” really is. From a HTA perspective, not only is there is difficulty in valuing
disease modifying interventions, but also implied risk to payers approving to re-
imburse these drugs at launch.METHODS: Primary research was undertaken with
payers and medical specialists to understand requirements to support disease
modification claims in HTA assessments. Various attributes were assessed during
in-depth discussions and through discrete choice conjoint. Over 100 respondents
were interviewed. RESULTS: The results show that that efficacy is themost impor-
tant attribute considered in disease modification for HTA assessments. The corre-
lation of biomarkers to clinical endpoints also has utility. The market access im-
plications for such products across geographies vary considerably. However, cost-
effectiveness remains a key driver in specific markets. CONCLUSIONS: Disease
modificationmeans delaying or halting the progression of a disease. Efficacy is the
most important single factor, with the evidence of magnitude and duration of
effect both being essential. However, efficacy alone is insufficient to support a
diseasemodification claim. Robust long termdata are also required and data show-
ing a meaningful improvement over currently available therapies. For regulators
and payers, acceptance of a diseasemodification claimmeans that payers take the
risk of reimbursing based on some extrapolation of data at launch. A commitment
to integrate a process of data review of outcomes over time linked with perfor-
mance will ensure any risk is mitigated.
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OBJECTIVES: Vietnam is an emerging pharmaceutical market that is both poorly
understood and undergoing significant change, with a target for introducing uni-
versal healthcare by 2014. The objective of the research was to place Vietnam’s
pricing and reimbursement environment in a context that brings its dynamics into
clearer focus and to gauge the likely future direction of its evolution.METHODS: A
comparison with its neighbour, China, was conducted based on interviews in both
markets with government advisers, health economists and health policy profes-
sors, as well as KOLs. A comparative analysis was then conducted of the market
access dynamics and drivers, as well as of policy reform plans. RESULTS: Many
similarities exist between the P&R environments of the twomarkets, although they
sit at different places along the P&R development continuum. In both, branded
drugs enjoy a considerable price premium over generics, which could be as high as
40 times in Vietnam. However, China is looking to change the situation by remov-
ing the premium for off-patent branded drugs. Despite efforts in to develop their
reimbursement system, direct-sale to hospitals is the primary revenue channel for
pharmaceuticals, with KOL-endorsement amajormarket access driver. In terms of
drug price regulation, the most commonly used measure is through the enforce-
ment of price caps. CONCLUSIONS: The Vietnamese P&R system is similar to that
of China 5-10 years ago. Several fundaments in terms the structure of the health
system, formalisation of the reimbursement system andmarket access drivers are
the same, but China is significantly further down the line than its neighbour. How-
ever, the health reform agendas of the two markets are both heading in similar
directions.
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OBJECTIVES: To present the empirical experience of new drug listing and reim-
bursement under Taiwan’s National Health Insurance (NHI), and to discuss the
performance of such mechanism. We also attempt to assess its impact on the
public access to pharmaceutical innovations. METHODS: The materials are based
on the documentation of Taiwan’sNHIDrug ReviewCommittee (DRC) over 15 years
period (19962010). We defined the criteria of pricing methods into 9 categories:
International Price Comparison, Comparison with Similar Products with Equiva-
lent Therapeutic Effects, Price Proportion Method, Price Addition, Orphan Drugs,
The Lowest Available International Price, Cost Analysis, Grouping and Others in-
cluded risk sharing managements. RESULTS: The total number of new drugs that
applied for NHI listing and reimbursement during 19962010 was 1103, and the
number of petition cases was 587(53%). The total number of new drugs with final
pricing decisions in this study was 802. Among them, 343 items were issued with
reimbursement pricewithout petition, and the remaining new drugs received their
reimbursement prices after petition on initial pricing decisions. The approved price
was averaged 69% of the international median prices, and was only 60% of inter-
national median prices among petition cases. The top threemethods of pricing are
Price Proportion Method, Equivalent Therapeutic Effect with Similar Product
(23.5%), and International Price Comparison. Because NHI faced financial crisis in
the past 10 years, the price of reimbursement came as approximately 70% of their
respective application prices in the recent years. More and more risk-sharing
agreements were introduced in the price negotiation. CONCLUSIONS: The poten-
tial pressure on theNHImay be even greater for growing financial gap in the future.
There are more efforts needed to seek the transparency in the listing and pricing
process for public good.
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OBJECTIVES: Tomeasure willingness to pay (WTP) for a QALY in Korea.METHODS:
A survey questionnaire based on EQ-5D scenarios was developed tomeasure QALY
improvements in Korea. Double bounded dichotomous choice (DBDC) questions
along with an open question were used to elicit WTPs. Each person was asked for
four scenarios chosen from 3-item EQ-5D scenarios ( 1 QALY) and an additional
scenario with live in perfect health for 1 year or die now (1 QALY). The sameWTP
questions were also repeated for QALY improvements of a family member instead
of self. The questionnaire also includedquestions ondemographics, disease status,
and a visual analog scale (VAS)measure of each scenario presented. Consistency of
each respondent was checked by matching ranks of five scenarios between WTPs
andQALY improvements either by VAS or Korean EQ-5D tariff. Initial bids for DBDC
questionswere determined by the quintiles of pilot surveyWTPs. Survey questions
for each study were fine tuned though two focus group interview sessions per
study. A general population sample was interviewed face-to-face in 2010.
RESULTS:Of the total 1,017 persons surveyed, 933 persons passed consistency test.
For those who passed consistency and not in Medical Aids program, WTP for a
QALY calculated from the final open questions (after DBDC questions) was 19 mil-
lion KRW (approximately 16,000 USD). WTP for family member were consistently
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